Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Hisamitsu Pharmaceutical (4530 JP): Focus Shifts to ADHD Treatment Patch and Other Upcoming Launches

Hisamitsu Pharmaceutical (4530 JP): Set to Benefit from Roaring OTC Business and New Rx Drug Launch

Hisamitsu Pharmaceutical (4530 JP): Strong Q3 Result Driven by Salonpas; FY23 Guidance Reiterated

Equity Bottom-Up

Hisamitsu Pharmaceutical Co / Equity Bottom-Up

<p>Hisamitsu Pharmaceutical is promoting a patch treatment culture globally. The company is the global leader in OTC topical analgesics patch market. The shares plunged 22% in last one-year, underperforming Nikkei 225, which gained 19%. Hisamitsu shares are trading near 52-week low. However, it will be wise not to indulge in bottom fishing, as the company is facing near-term headwinds for its mainstay products. This insight has analyzed the risks being faced by its key products as well as upside risks arising from new products. Investors should wait for Q2 earnings announcement before taking any positions on the stock.</p>

Hisamitsu Pharmaceutical is promoting a patch treatment culture globally. The company is the global leader in OTC topical analgesics patch market. The shares plunged 22% in last one-year, underperforming Nikkei 225, which gained 19%. Hisamitsu shares are trading near 52-week low. However, it will be wise not to indulge in bottom fishing, as the company is facing near-term headwinds for its mainstay products. This insight has analyzed the risks being faced by its key products as well as upside risks arising from new products. Investors should wait for Q2 earnings announcement before taking any positions on the stock.

Hisamitsu Pharmaceutical (4530 JP): Avoid as More Pain Ahead